Compares a daily hormone pill with vitamin E for migraine linked to menstruation
Tests a daily hormone pill against vitamin E in women with menstrual or perimenopausal migraine.
Plain-language title generated from the registry record
Registry title: (WHAT!) – RCT: Open-label randomized controlled trial for the effects of continuous daily use of ethinylestradiol/levonorgestrel (30/150 µg/day) compared with vitamin E (400 IU/day) in the treatment of menstrually-related migraine and perimenopausal migraine
Key facts
- Where
- Leiden, NetherlandsSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Source: NCT04007874, who can take part
Where in Netherlands
- Leiden University Medical CenterLeiden, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Leids Universitair Medisch Centrum (LUMC)
- Trial code
- NCT04007874EU 2024-517127-40-00
- Record updated
- 25 March 2026
- Original description
To evaluate the effect of continuous daily use of ethinylestradiol/levonorgestrel (30/150 pg/day) compared with vitamin E (400 lU/day) in women: 1. Trial 1: with menstrually-related migraine or pure menstrual migraine; 2. Trial 2: with perimenopausal migraine. The primary efficacy endpoint for the trials is the mean change from baseline in mean monthiy migraine days in a 28-day period as assessed at the 12-week timepoint (weeks 9-12).Read full original descriptionShow less
(WHAT!) – RCT: Open-label randomized controlled trial for the effects of continuous daily use of ethinylestradiol/levonorgestrel (30/150 µg/day) compared with vitamin E (400 IU/day) in the treatment of menstrually-related migraine and perimenopausal migraine
To evaluate the effect of continuous daily use of ethinylestradiol/levonorgestrel (30/150 pg/day) compared with vitamin E (400 lU/day) in women: 1. Trial 1: with menstrually-related migraine or pure menstrual migraine; 2. Trial 2: with perimenopausal migraine. The primary efficacy endpoint for the trials is the mean change from baseline in mean monthiy migraine days in a 28-day period as assessed at the 12-week timepoint (weeks 9-12).
Inclusion: Trial 1: Menstrually-related migraine: Female - Age ^ 18 - Menstrually-related migraine or pure menstrual migraine - Demonstrated at least 80% compliance with eDiary during baseline period - No or stable for at least two months on prophylactic medication Trial 2: Perimenopausal migraine: Female - AgeS 18 In the early menopausal transition phase (a difference of 7 days or more in length of consecutive cycles, which should occur at least twice in a period of 12 menstrual cycles) - Demonstrated at least 80% compliance with eDiary during baseline period - No or stable for at least two months on prophylactic medication.
Exclusion: Smoking - Migraine with aura - Chronic migraine with 15 or more headache days per month/with 8 or more migraine days per month - Medication-overuse headache (ICHD-3 criteria) - Women who are breastfeeding, pregnant, or planning to become pregnant - Oral contraceptive use and not willing to undergo washout period (stop for two consecutive months) - Vitamin E use at start of the study - Use of other sex hormone containing treatments - Increased risk of VTE: history of VTE or thrombophlebitis, hereditary predisposition for VTE (APC resistance, protein C or S deficiency, antithrombin deficiency), VTE in first-degree family member at young age, long term immobilisation - Increased risk of ATE: history of ATE, hereditary predisposition for ATE (hyperhomocysteinemia, antiphospholipid antibodies), ATE in first-degree family member at young age, diabetes mellitus, total cholesterol ≥ 6.5 - Other contraindication for oral contraceptives: liver malignancy, schistosomiasis, HIV/aids, use of immunosuppressives, tuberculosis, sex-hormone-dependent malignancies (breast, endometrial or ovary carcinomas), pancreatitis, vaginal bleeding with unknown cause, other diseases that can influence vessels (malignancies, heart valve disorders, atrial fibrillation, SLE, haemolytic uremic syndrome, chronic inflammatory bowel disease, sickle cell disease) - Contraindication for vitamin E: vitamin K deficiency - Hypersensitivity for any of the compounds in oral contraceptive or vitamin E - Spontaneous postmenopausal status (menstrual bleedings have ceased for 12 consecutive months) - Iatrogenic postmenopausal status - Inability to complete the electronic diary in an accurate manner - Any serious illness that can compromise study participation.